A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies

2024-514777-22-00 Protocol FS120-19101 Human pharmacology (Phase I) - First administration to humans Ended

Start 7 Feb 2022 · End 23 Jan 2025 · Status Ended · 1 EU/EEA countries · 8 sites · Protocol FS120-19101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 277
Countries 1
Sites 8

Advanced Malignancies

Key facts

Sponsor
Invox Pharma Limited
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
7 Feb 2022 → 23 Jan 2025
Decision date (initial)
2024-07-18
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-514777-22-00
EudraCT number
2021-002820-19
ClinicalTrials.gov
NCT04648202

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Malignancies

VersionLevelCodeTermSystem organ class
21.0 LLT 10048683 Advanced cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Invox Pharma Limited

Sponsor organisation
Invox Pharma Limited
Address
Suite 2, First Floor Westworks, 195 Wood Lane First Floor Westworks 195 Wood Lane
City
London
Postcode
W12 7FQ
Country
United Kingdom

Scientific contact point

Organisation
Invox Pharma Limited
Contact name
invoX Pharma Clinical Trials

Public contact point

Organisation
Invox Pharma Limited
Contact name
invoX Pharma Clinical Trials

Locations

1 EU/EEA country · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 113 8
Rest of world
Israel, United States
164

Investigational sites

Spain

8 sites · Ended
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario 12 De Octubre
Oncology, Bloque D, Avenida De Cordoba Sn, Madrid
Hospital Clinico Universitario De Valencia
Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Quironsalud Barcelona
Oncology, Placa D'alfonso Comin 5-7, 08023, Barcelona
Hospital Universitario Quironsalud Madrid
Oncology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Clinic De Barcelona
Oncology, Calle Villarroel 170, 08036, Barcelona
Hospital Germans Trias I Pujol
Oncology, Carretera Canyet 1a Planta, 08916, Badalona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2022-02-07 2022-03-17 2024-08-02

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-16 Spain Acceptable with conditions
2024-07-18
2024-07-18